Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Blum

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cambridge Prisms. Coastal Futures|August 29, 2025
What is coastal subsidence?Torbjörn E Törnqvist, Michael D Blum
The Journal of Pediatrics|July 4, 2021
Real-World Evidence for Assessing Treatment Effectiveness and Safety in Pediatric PopulationsDaniel B Horton, Michael D Blum, Mehmet Burcu
Clinical Pharmacology and Therapeutics|August 29, 2020
International Collaboration in Real-World Evidence Generation for Direct Acting Oral Anti-CoagulantsPeter Arlett, Xavier Kurz, Katherine Soltys, et al.
Pharmacoepidemiology and Drug Safety|November 7, 2019
Using real-world data to evaluate biosimilar switchingSarah K Dutcher, Efe Eworuke, Michael D Blum, et al.
Pharmacoepidemiology and Drug Safety|March 2, 2017
Response to Consumer Healthcare Products Association letter to "Trend in rates of acetaminophen-related adverse events in the United States"Tracy Pham, Jacqueline M Major, Grace Chai, et al.
Pharmacoepidemiology and Drug Safety|March 13, 2020
Real-world evidence to support regulatory decision-making for medicines: Considerations for external control armsMehmet Burcu, Nancy A Dreyer, Jessica M Franklin, et al.
The Journal of Biological Chemistry|September 27, 2002
T cell-specific expression of the murine CD3delta promoterHong-Bin Ji, Anita Gupta, Susumu Okamoto, et al.
The Journal of Infectious Diseases|January 23, 2010
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adultsDaniel M Musher, Susan B Manof, Charlie Liss, et al.
Transplantation|March 19, 2008
Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety databaseGeorge H Steele, Anthony B Adamkovic, Laura A Demopoulos, et al.
Pharmacoepidemiology and Drug Safety|December 13, 2019
Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectivenessSarah K Dutcher, Elnara Fazio-Eynullayeva, Efe Eworuke, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cambridge Prisms. Coastal Futures|August 29, 2025
What is coastal subsidence?Torbjörn E Törnqvist, Michael D Blum
The Journal of Pediatrics|July 4, 2021
Real-World Evidence for Assessing Treatment Effectiveness and Safety in Pediatric PopulationsDaniel B Horton, Michael D Blum, Mehmet Burcu
Clinical Pharmacology and Therapeutics|August 29, 2020
International Collaboration in Real-World Evidence Generation for Direct Acting Oral Anti-CoagulantsPeter Arlett, Xavier Kurz, Katherine Soltys, et al.
Pharmacoepidemiology and Drug Safety|November 7, 2019
Using real-world data to evaluate biosimilar switchingSarah K Dutcher, Efe Eworuke, Michael D Blum, et al.
Pharmacoepidemiology and Drug Safety|March 2, 2017
Response to Consumer Healthcare Products Association letter to "Trend in rates of acetaminophen-related adverse events in the United States"Tracy Pham, Jacqueline M Major, Grace Chai, et al.
Pharmacoepidemiology and Drug Safety|March 13, 2020
Real-world evidence to support regulatory decision-making for medicines: Considerations for external control armsMehmet Burcu, Nancy A Dreyer, Jessica M Franklin, et al.
The Journal of Biological Chemistry|September 27, 2002
T cell-specific expression of the murine CD3delta promoterHong-Bin Ji, Anita Gupta, Susumu Okamoto, et al.
The Journal of Infectious Diseases|January 23, 2010
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adultsDaniel M Musher, Susan B Manof, Charlie Liss, et al.
Transplantation|March 19, 2008
Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety databaseGeorge H Steele, Anthony B Adamkovic, Laura A Demopoulos, et al.
Pharmacoepidemiology and Drug Safety|December 13, 2019
Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectivenessSarah K Dutcher, Elnara Fazio-Eynullayeva, Efe Eworuke, et al.
Pageof 2